While both conditions arise from identical pituitary adenomas, their clinical timelines generate distinct physical manifestations. Understanding these diagnostic differences explains why medical teams assess gigantism with different disability evaluation criteria than adult-onset cases.
| Clinical Marker | Pituitary Gigantism | Acromegaly | Familial Tall Stature |
|---|---|---|---|
| Onset Timing | Childhood (Pre-epiphyseal fusion) | Adulthood (Post-epiphyseal fusion) | Normal childhood growth trajectory |
| Skeletal Manifestation | Extreme longitudinal bone length | Acral overgrowth (hands, jaw, skull) | Proportionate skeletal architecture |
| IGF-1 & GH Serum Levels | Massively elevated; dysregulated | Consistently elevated; dysregulated | Normal physiological baseline |
| Cardiomegaly Risk | Extremely high; early onset | High; develops over decades | Matches general population baseline |
| Mobility Prognosis | Severe functional impairment by age 30 | Localized joint arthropathy; manageable | Normal physical performance |
When tumors manifest in adulthood, fused growth plates prevent vertical stretching. Instead, the patient develops acromegaly: broader hands, thickened facial features, and expanding jawbones. Gigantism patients, however, suffer both burdens. They sustain the massive vertical expansion of open epiphyses alongside the acral widening, facial changes, and visceral enlargement seen in acromegaly.
